Article Text

Download PDFPDF

5PSQ-117 Determination of genetic polymorphisms in the dihydropyrimidine dehydrogenase gene in a patient with gastric adenocarcinoma treated with fluoropyrimidines: a case report
  1. A Ganfornina Andrades,
  2. C Rodriguez Moreta,
  3. M Corrales Paz,
  4. MJ Martinez Bautista,
  5. MV Manzano Martin
  1. Puerta del Mar University Hospital, Pharmacy, Cadiz, Spain


Background and importance Fluoropyrimidines are a foundational component of chemotherapy for solid tumour malignancies. The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase enzyme (DPD) deficiency, which can result from deleterious polymorphisms in the gene encoding DPD (DPYD). Partial or total deficiency of this enzyme is related to severe toxicity and in some cases it can cause the death of the patient.

Aim and objectives To determine polymorphisms in the DPYD gene in a patient with gastric adenocarcinoma treated with fluoropyrimidines in order to avoid overexposure and toxicity associated with these drugs.

Material and methods A 66-year-old man was diagnosed with stage III gastric tubular adenocarcinoma. The treatment plan consisted of four cycles of neoadjuvant chemotherapy with the FLOT protocol: docetaxel 50 mg + calcium folinate 200 mg + oxaliplatin 85 mg + 5-fluorouracil (fluoropyrimidine) 2600 mg as a 24-hour intravenous infusion, every 14 days; followed by surgical intervention. Before starting the chemotherapy regimen, determination of DPD deficiency was requested.

Results The results showed mutation c.1236 G/A (HapB3) for the DPYD gene, which indicated overexposure to fluoropyrimidines and increased toxicity like diarrhoea, mucositis, neutropenia and neurotoxicity. Due to the polymorphism detected in DPYD gene, a 5-fluorouracil dose adjustment was required. The patient received four cycles of chemotherapy from April to June 2021 according to the dose recommendations of the oncology pharmacist. Treatment was started with a 50% dose reduction of 5-fluorouracil. After the first infusion, it was well tolerated with few reported adverse side effects such as low-grade fever, xerostomia and neutropenia. Neutropenia was successfully treated with granulocyte colony stimulating factors and the patient was able to continue the treatment, increasing the 5-fluorouracil dose by 25% in the last two cycles. Despite excellent tolerance to chemotherapy, the patient died after gastrectomy due to postsurgical complications.

Conclusion and relevance Genetic analysis for the determination of polymorphisms in the DPYD gene allows us to predict the potentially serious toxicity of fluoropyrimidines, encouraging the individualised use of these drugs. In our case, the patient was at risk of developing severe toxicity so a dose adjustment of 5-fluorouracil was required.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.